Novel Double-Antigen Sandwich Immunoassay for Human Hepatitis B Core Antibody

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical and Vaccine Immunology

• Publication date

  2010-01-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1128/CVI.00457-09PMID 20107008PMCID PMC2837963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients.

  2009cited by this paper
• Can the serological status of “anti‐HBc alone” be considered a sentinel marker for detection of “occult” HBV infection?

  2008cited by this paper
• Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera.

  2008cited by this paper
• Natural History of Hepatitis B Virus Infection in Renal Transplant Recipients–A Fifteen‐Year Follow‐Up

  2007cited by this paper
• Hepatitis B virus DNA in serum of 'anti-HBc only'-positive healthy Lebanese blood donors: significance and possible implications.

  2007cited by this paper
• Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance.

  2006cited by this paper
• Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication.

  2004cited by this paper
• Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study.

  2003cited by this paper
• Stability and Morphology Comparisons of Self-AssembledVirus-Like Particles from Wild-Type and Mutant Human Hepatitis B VirusCapsidProteins

  2003cited by this paper
• Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti‐HBc: implications for transfusion transmission and donor screening

  2003cited by this paper
• The significance of 'anti-HBc only' in the clinical virology laboratory.

  2003cited by this paper
• Hepatitis B virus markers in anti‐HBc only positive individuals *

  2001cited by this paper
• Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.

  2001cited by this paper
• High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum.

  2000cited by this paper
• Serological pattern “anti‐HBc alone”: Report on a workshop

  2000cited by this paper
• Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.

  1999cited by this paper
• The long‐term course of chronic hepatitis B

  1999cited by this paper
• Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc.

  1998cited by this paper
• Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly.

  1995cited by this paper
• Detection of HBs antigen in "anti-HBc alone" positive sera.

  1994cited by this paper
• The structure of hepadnaviral core antigens. Identification of free thiols and determination of the disulfide bonding pattern.

  1992cited by this paper
• Stability of the recombinant hepatitis B core antigen

  1992cited by this paper
• Characterization of a reduction-sensitive factor from human plasma responsible for apparent false activity in competitive assays for antibody to hepatitis B core antigen

  1991cited by this paper
• Improvement in the specificity of assays for detection of antibody to hepatitis B core antigen

  1991cited by this paper
• Unsatisfactory specificities and sensitivities of six enzyme immunoassays for antibodies to hepatitis B core antigen

  1989cited by this paper
• Enzyme immunoassay for anti-hepatitis B core (HBc) immunoglobulin G1 and significance of low-level results in competitive assays for anti-HBc

  1989cited by this paper
• Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS.

  1989cited by this paper
• Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders.

  1975cited by this paper

• Advancing syphilis diagnosis: multi-phase study evaluation of a TpN17-based double-antigen sandwich ELISA for detecting Treponema pallidum specific antibodies

  2025influential citation
• Enzyme-linked immunosorbent STI assays: development, current status and future perspective.

  2025cites this paper
• Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

  2025cites this paper
• Development and optimization of a double antigen sandwich ELISA detecting for Senecavirus A antibodies based on VP2 protein

  2024cites this paper
• Clinical Features and Transition of Acute Hepatitis B Virus Infection

  2024cites this paper
• Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis

  2024cites this paper
• Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation

  2023cites this paper
• Lateral Flow Assay for Hepatitis B Detection: A Review of Current and New Assays

  2023cites this paper
• Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

  2023cites this paper
• Dose–response relationship between qAnti‐HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase based on liver biopsy

  2022cites this paper
• Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan

  2022cites this paper
• Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients

  2022cites this paper
• Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure

  2022influential citation
• Review article: novel biomarkers in hepatitis B infection

  2022cites this paper
• A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN.

  2022cites this paper
• Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years

  2021cites this paper
• Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance

  2021cites this paper
• Handheld Microfluidic Filtration Platform Enables Rapid, Low-Cost, and Robust Self-Testing of SARS-CoV-2 Virus.

  2021cites this paper
• A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients

  2021influential citation
• Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation

  2021cites this paper
• Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection

  2021cites this paper
• Viral and Host Factors Affecting Disease Progression of Hepatitis B Virus Infection

  2021cites this paper
• Association of anti‐HBc and liver inflammation in HBeAg‐negative chronic hepatitis B virus‐infected patients with normal ALT and detectable HBV DNA

  2021cites this paper
• Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.

  2021cites this paper
• Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients

  2021cites this paper
• The Matching Status Between Donor and Recipient Hepatitis B Seroepidemiology Makes a Difference in Liver Transplantation for Hepatocellular Carcinoma

  2020cites this paper
• The serum interleukin-26 level is a potential biomarker for chronical hepatitis B

  2020cites this paper
• Specific determination of hepatitis B e antigen by antibodies targeting precore unique epitope facilitates clinical diagnosis and drug evaluation against hepatitis B virus infection

  2020cites this paper
• Producción y evaluación de antígenos recombinantes para el diagnóstico serológico y la generación de vacunas para el control de la anaplasmosis bovina

  2020cites this paper
• Prognostic value of anti‐HBc quantification in hepatitis B virus related acute‐on‐chronic liver failure

  2020cites this paper
• Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT.

  2020cites this paper
• Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels

  2020cites this paper
• Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy

  2019cites this paper
• Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen‐Seronegative Patients

  2019cites this paper
• Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection.

  2019cites this paper
• Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg‐Positive Children With a Normal Alanine Aminotransferase Level

  2019cites this paper
• Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus

  2019cites this paper
• Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers

  2019cites this paper
• Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B

  2019cites this paper
• Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance.

  2019cites this paper
• Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B

  2019cites this paper
• Development and evaluation of a double-antigen sandwich ELISA to identify Anaplasma marginale–infected and A. centrale–vaccinated cattle

  2019cites this paper
• Performance Evaluation of a Prototype Architect Antibody Assay for Babesia microti

  2018cites this paper
• Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

  2018cites this paper
• A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients.

  2018cites this paper
• Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment‐naïve CHB patients

  2018cites this paper
• Viral Factors Affecting Disease Progression

  2018cites this paper
• Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.

  2018cites this paper
• Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near‐normal alanine aminotransferase levels

  2018cites this paper
• Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

  2018cites this paper
• PERFORMANCE EVALUATION OF A PROTOTYPE ARCHITECT ANTIBODY ASSAY FOR BABESIA 1

  2018cites this paper
• Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal

  2018cites this paper
• New viral biomarkers for Hepatitis B: Are we able to change practice?

  2018cites this paper
• Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma

  2018cites this paper
• Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B

  2017cites this paper
• Europium (III) chelate microparticle-based lateral flow immunoassay strips for rapid and quantitative detection of antibody to hepatitis B core antigen

  2017cites this paper
• Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B.

  2017cites this paper
• Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long‐term entecavir

  2017cites this paper
• Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase

  2017cites this paper
• Long‐term outcome of inactive and active, low viraemic HBeAg‐negative‐hepatitis B virus infection: Benign course towards HBsAg clearance

  2017cites this paper
• Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG‐administered infants born to HBsAg positive mothers

  2017cites this paper
• Current advances in the elimination of hepatitis B in China by 2030

  2017cites this paper
• Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV‐related HCC

  2016cites this paper
• Chlamydia trachomatis Pgp3 Antibody Persists and Correlates with Self-Reported Infection and Behavioural Risks in a Blinded Cohort Study

  2016cites this paper
• Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos ( t ) ide analogues

  2016cites this paper
• New perspectives of biomarkers for the management of chronic hepatitis B

  2016cites this paper
• Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients

  2016cites this paper
• On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B

  2016cites this paper
• Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B

  2016cites this paper
• Revisiting the Natural History of Chronic HBV Infection

  2016cites this paper
• Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues

  2015cites this paper
• The Expression of TLR-9, CD86, and CD95 Phenotypes in Circulating B Cells of Patients with Chronic Viral Hepatitis B or C before and after Antiviral Therapy

  2015cites this paper
• Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

  2015cites this paper
• Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping.

  2015cites this paper
• Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon

  2015cites this paper
• Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection.

  2015cites this paper
• Significance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination.

  2014cites this paper
• Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B

  2014cites this paper
• Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment

  2013cites this paper
• Anti-hbc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis b patient and in predicting therapeutic effect

  2013cites this paper
• Anti-hbc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途

  2013cites this paper
• Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.

  2013cites this paper
• Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis B

  2012cites this paper
• Development and application of a double-antigen sandwich ELISA

  2012cites this paper
• Serum IL-33 Levels Are Associated with Liver Damage in Patients with Chronic Hepatitis C

  2012cites this paper
• Hepatitis B core antibody testing in Indian blood donors: A double-edged sword!

  2012cites this paper
• Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients

  2012cites this paper
• Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core

  2012cites this paper
• Development and Application of a Double-Antigen Sandwich Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Porcine Circovirus 2

  2012cites this paper
• High Frequency of CD4+CXCR5+ TFH Cells in Patients with Immune-Active Chronic Hepatitis B

  2011cites this paper
• Evidencias serológicas y moleculares de la circulación del virus de la hepatitis E en Cuba

  2011cites this paper
• World Journal of Hepatology

  year unknowninfluential citation